Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Analysts Are Bullish on These Healthcare Stocks: AN2 Therapeutics, Inc. (ANTX), Heron Therapeutics (HRTX)
Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its First-Quarter Results
Heron Therapeutics, Inc. (NASDAQ:HRTX) just released its latest first-quarter results and things are looking bullish. Results overall were solid, with revenues arriving 5.1% better than analyst f
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript
Express News | Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Heron Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 70.65% Needham → $5 Reiterates Buy → Buy 04/23/2024 104.78% Capital One → $6 Initiates Coverage
Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ...
Q1 2024 Heron Therapeutics Inc Earnings Call
Earnings Call Summary | Heron Therapeutics(HRTX.US) Q1 2024 Earnings Conference
The following is a summary of the Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript:Financial Performance:Heron Therapeutics Q1 net revenue was $34.6 million, up from $29.6 million year
Heron Therapeutics: A Strong Buy on Surging Sales and Strategic Partnerships
Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript
Express News | Heron Therapeutics Shares Reverse Premarket Course, Last Down 1.4%
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
Heron Therapeutics Inc. Q1 Loss Decreases, Beats Estimates
Express News | Heron Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Reaffirmed Its FY24 Revenue Guidance
Heron Therapeutics | 10-Q: Quarterly report
Express News | Heron Therapeutics Shares up 5% Premarket After Q1 Results
Heron Therapeutics Still Sees 2024 Net Product Revenue $138M-$158M >HRTX
Heron Therapeutics Still Sees 2024 Net Product Revenue $138M-$158M >HRTX
Express News | Heron Therapeutics Reaffirms FY24 Revenue $138.0M-$158.0M Vs $144.875M Est
Express News | Heron Therapeutics Inc - Reaffirms FY Guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted Ebitda